Core Viewpoint - The company, 诺唯赞 (688105.SH), expects a net loss of between 10 million to 20 million yuan for the fiscal year 2025, primarily due to various operational challenges and external market conditions [1]. Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company in the range of -20 million to -10 million yuan for 2025 [1]. - The expected net profit, excluding non-recurring gains and losses, is projected to be between -85 million to -70 million yuan [1]. Group 2: Revenue and Cost Factors - The company's revenue is expected to remain stable compared to the previous year, largely impacted by an increase in the value-added tax rate on biological products from 3% to 13%, adversely affecting overall revenue and profitability [1]. - The company has increased its sales expenses year-on-year as it actively expands its innovative business and overseas markets, which has negatively impacted current operating results [1]. Group 3: Strategic Initiatives - The company is responding to external environmental changes by enhancing technology and product research and development, optimizing cost reduction and efficiency measures, and strengthening its technological innovation capabilities and market competitiveness [1]. - The company has made provisions for certain credit impairment losses and asset impairment losses based on actual circumstances and prudence, which have also negatively affected current operating results [1].

Core Viewpoint - The company, 诺唯赞 (688105.SH), expects to report a net loss attributable to shareholders of the parent company ranging from -20 million to -10 million yuan for the fiscal year 2025, with a net profit excluding non-recurring gains and losses projected between -85 million and -70 million yuan [1] Group 1: Revenue and Profitability - The company's expected revenue for the reporting period is projected to be roughly flat compared to the previous year, primarily due to an increase in the value-added tax rate on biological products from 3% to 13%, negatively impacting overall revenue and profitability [1] - The company anticipates a net loss for the fiscal year 2025, reflecting the adverse effects of the tax rate adjustment on its financial performance [1] Group 2: Strategic Initiatives - In response to external environmental changes, the company is actively enhancing its technology and product research and development, optimizing cost reduction and efficiency measures to improve operational efficiency [1] - The company is maintaining a strong market investment intensity and is actively expanding its innovative business and overseas markets, which has led to an increase in sales expenses compared to the previous year, negatively affecting current operating results [1] Group 3: Impairment Losses - The company has made provisions for certain credit impairment losses and asset impairment losses based on actual circumstances and a principle of prudence, which has also contributed to the negative impact on current operating results [1]

证券代码：688105 证券简称：诺唯赞 公告编号：2026-002 南京诺唯赞生物科技股份有限公司 2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 经南京诺唯赞生物科技股份有限公司（以下简称"公司"）财务部门初步测 算，预计公司2025年度： 1. 实现归属于母公司所有者的净利润-2,000万元至-1,000万元。 2. 实现归属于母公司所有者的扣除非经常性损益的净利润-8,500万元至 -7,000万元。 （三）本次业绩预告相关财务数据未经注册会计师审计。 三、本期业绩变化的主要原因 2025年度，公司预计出现亏损，主要原因如下： 1.报告期内，预计实现的营业收入与上年同期基本持平，主要系公司生物制 品类产品增值税率由3%调整至13%，对整体营收与盈利产生不利影响。 2.报告期内，公司积极应对外部环境变化影响，加强技术与产品研发，优化 降本增效举措，提升经营效率，不断巩固公司科技创新实力与 ...

Core Viewpoint - The company, Novozymes, is forecasting a net loss for the year 2025, with expected losses ranging from 20 million to 10 million yuan for net profit attributable to shareholders, and a net profit excluding non-recurring losses expected to be between 85 million and 70 million yuan [1] Group 1: Financial Performance - The company anticipates that its operating revenue will remain largely unchanged compared to the previous year, primarily due to an increase in the value-added tax rate on biological products from 3% to 13%, negatively impacting overall revenue and profitability [1] - The projected net loss for 2025 is attributed to various factors, including increased sales expenses due to the company's efforts to expand innovative business and overseas markets [1] Group 2: Strategic Initiatives - The company is actively responding to external environmental changes by enhancing technology and product research and development, optimizing cost reduction and efficiency measures, and improving operational efficiency [1] - The company is maintaining a strong market investment intensity to consolidate its technological innovation capabilities and market competitiveness [1] Group 3: Impairment Losses - The company has made provisions for certain credit impairment losses and asset impairment losses based on actual circumstances and a principle of prudence, which has also negatively impacted the current operating results [1]

Group 1 - The core business of the company includes research and development of functional proteins and high molecular organic materials, with a focus on biological reagents, in vitro diagnostics, and antibody drug development [2] - As of September 30, the company reported a total revenue of 952 million yuan for the period from January to September 2025, representing a year-on-year decrease of 3.40%, and a net profit attributable to shareholders of 6.6152 million yuan, down 63.57% year-on-year [2] - The company has a total of 9,447 shareholders, which is an increase of 9.90% compared to the previous period, while the average circulating shares per person decreased by 9.01% to 42,101 shares [2] Group 2 - The company has distributed a total of 731 million yuan in dividends since its A-share listing, with 611 million yuan distributed over the past three years [3] Group 3 - On January 22, the company's stock price increased by 0.70%, with a trading volume of 35.0056 million yuan [1] - The financing buy-in amount on January 22 was 1.6545 million yuan, while the financing repayment was 3.3677 million yuan, resulting in a net financing buy-in of -1.7132 million yuan [1] - The total balance of margin trading for the company as of January 22 was 123 million yuan, accounting for 1.43% of the circulating market value, which is above the 90th percentile level over the past year [1]

证券代码：688105 证券简称：诺唯赞 公告编号：2026-001 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/20 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 6 6 月 | 年 | 月 | 19 | 日~2026 | 年 | 18 日 | | 预计回购金额 | 500万元~1,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 12.77万股 | | | | | | | | 累计已回购股数占总股本比例 | 0.03% | | | | | | | ...

诺唯赞公告称，公司于2025年6月19日通过回购股份议案，预计用500万元 - 1000万元自有资金，以不超 30元/股的价格回购股份，用于员工持股计划或股权激励，回购期限至2026年6月18日。截至2025年12月 31日，公司累计回购12.77万股，占总股本的0.03%，累计已回购金额299.97万元，实际回购价格区间为 23.06元/股 - 24.36元/股。 ...

Core Insights - The GLP-1 sector is experiencing significant growth potential, and the company is leveraging its upstream raw material supply advantages to explore the GLP-1 peptide raw material market [2] - The company has successfully provided hundreds of kilograms of supply to multiple domestic clients during the 2024 reporting period, complying with GMP standards [2] - The company is focused on enhancing its product and service advantages across the GLP-1 fermentation recombinant method value chain, addressing client needs for product quality, cost, and capacity [2] Business Operations - The company has engaged in compliance submissions and audits with several clients, ensuring adherence to regulatory standards [2] - Ongoing efforts include advancing the DMF filing for core enzyme raw materials and intermediates to support clients' compliance submissions [2] - The business faces uncertainties in future performance due to market competition, supply-demand changes, technological iterations, and geopolitical factors [2]

Group 1 - The core viewpoint of the article is that the company, 诺唯赞, has confirmed it is not planning any changes to its controlling rights as of now [1] Group 2 - The company responded to investor inquiries on its interactive platform regarding the status of its controlling rights [1]

Core Viewpoint - The company, Novozymes, is focused on providing core raw materials and reagents necessary for the production of semaglutide through synthetic biology fermentation methods, catering to various downstream clients [1] Group 1: Product Offerings - The GLP-1 product line includes high specificity and high-capacity raw enzymes and various specifications of intermediate peptides [1] - The company has developed comprehensive quality control testing kits to ensure product reliability [1] Group 2: Client Engagement - Novozymes has successfully supplied hundreds of kilograms of materials to multiple domestic clients [1] - The company offers customized process optimization solutions to enhance production efficiency for its clients [1] Group 3: Production Scope - Currently, the company does not engage in the production of related weight-loss medications [1]